Plant Name: Aloe vera
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; DRD4; ADRA2C; ADRA2A; ADRA2B; HCAR2; | |
| NPSR1; CXCR1; NMUR2; TSHR; | |
| GABBR1; | |
| ALPL; RECQL; TDP1; PLA2G1B; BLM; GLA; FAAH; CTDSP1; P4HB; TERT; PKM; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B10; AKR1B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; NOX4; USP2; GSTK1; TNKS; TNKS2; PYGL; APEX1; POLB; GDA; | |
| PTPN1; CDC25B; | |
| ACHE; GAA; | |
| GABRR1; | |
| CFTR; | |
| TRPA1; | |
| AKT1; MET; CAMK2B; NEK6; CSNK2A1; DAPK1; SYK; FLT3; PKN1; SRC; IGF1R; PTK2; AURKB; GSK3B; KDR; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; NEK2; CDK6; | |
| CA7; CA3; CA14; CA5B; CA5A; CA6; CA1; CA12; CA4; CA2; CA9; | |
| PPARA; PPARG; PPARD; | |
| AR; | |
| NR1I2; | |
| ESRRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; TYR; XDH; | |
| MMP13; MMP3; MMP2; MMP9; MMP1; | |
| BACE1; | |
| TLR2; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| KMT2A; | |
| SLC6A1; SLC6A11; | |
| ABCC1; ABCG2; | |
| LMNA; FABP2; FABP4; MAPT; FABP3; FABP5; THPO; HTT; NPC1; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GSTK1 | Glutathione S-transferase kappa 1 | Q9Y2Q3 | CHEMBL4491 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | GDA | Guanine deaminase | Q9Y2T3 | CHEMBL3129 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.013E-13 | 1.410E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.264E-13 | 2.006E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.867E-12 | 1.846E-09 | AURKB, CA2, CA7, CFTR, HCAR2, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.445E-11 | 5.725E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.483E-11 | 5.751E-09 | ADRA2A, AURKB, CA2, CA7, CDK6, CFTR, HCAR2, HIF1A, HTT, KDR, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2, TRPA1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.655E-11 | 6.085E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.717E-11 | 1.726E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.277E-10 | 2.398E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.494E-09 | 3.459E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.089E-08 | 1.310E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.856E-08 | 3.189E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.700E-08 | 4.008E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 3.982E-08 | 4.272E-06 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.238E-08 | 5.564E-06 | AHR, AR, ESR1, ESR2, ESRRA, NR1I2, PIM1, PPARA, PPARD, PPARG, SRC |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.768E-08 | 6.010E-06 | AKT1, HIF1A, LMNA, P4HB, PPARD, PTGS2, SRC, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.096E-08 | 7.254E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 8.518E-08 | 8.355E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 9.403E-08 | 9.100E-06 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC, SYK |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 9.995E-08 | 9.588E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.273E-07 | 1.190E-05 | ADRA2A, ADRA2B, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, ESRRA, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, HCAR2, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.567E-07 | 1.428E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1, SYK |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.708E-07 | 1.524E-05 | ADRA2A, ADRA2B, ADRA2C, DRD4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.568E-07 | 2.954E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.953E-07 | 3.224E-05 | AR, ESR1, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG, SRC |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.059E-07 | 5.451E-05 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BLM, CAMK2B, CDC25B, CDK1, CDK6, CSNK2A1, CTDSP1, ESR1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, HPGD, HTT, KMT2A, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1I2, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.181E-06 | 8.666E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.420E-06 | 1.027E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.420E-06 | 1.027E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.677E-06 | 1.194E-04 | AKT1, FABP3, FFAR1, PPARG, PTGS2, SRC, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.257E-06 | 1.555E-04 | AR, CDK1, ESR1, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.738E-06 | 1.863E-04 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.984E-06 | 2.002E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.531E-06 | 2.295E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 3.950E-06 | 2.537E-04 | ADRA2B, ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CDK6, CTDSP1, CYP1B1, ESR1, ESRRA, GSK3B, HIF1A, KDR, KMT2A, MAPT, PIK3R1, PIM1, PPARD, PPARG, PTGS2, PTK2, SRC, STAT6, SYK, TERT, THPO, TLR2, XDH |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.077E-06 | 2.603E-04 | ADRA2A, ADRA2B, ADRA2C, AKT1, SRC |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 4.077E-06 | 2.603E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.794E-06 | 3.000E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 5.522E-06 | 3.359E-04 | CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 6.586E-06 | 3.951E-04 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AR, AURKB, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GDA, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, KMT2A, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.025E-06 | 4.191E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 9.129E-06 | 5.343E-04 | AKT1, AR, DAPK1, HTT, LMNA, SRC, TERT |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.019E-05 | 5.839E-04 | APEX1, CFTR, NOX4, PPARG, PTGS2, SLC6A1, TP53, TYR |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.074E-05 | 6.122E-04 | BLM, GSK3B, HIF1A, HTT, NUAK1, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.103E-05 | 6.221E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.106E-05 | 6.221E-04 | AHR, ESR1, PPARA, TERT |
| BP | GO:0009987; cellular process | GO:0071216; cellular response to biotic stimulus | 1.242E-05 | 6.845E-04 | AXL, GSK3B, NFKB1, PPARD, SRC, SYK, TLR2, TP53 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.326E-05 | 7.276E-04 | ADRA2A, ADRA2C, AHR, AXL, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, PPARG, TLR2, TP53, TTR, TYR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.358E-05 | 7.431E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.370E-05 | 7.468E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.481E-05 | 8.009E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, BLM, CAMK2B, FLT3, GLA, HPGD, KMT2A, MAPT, NFKB1, PTGS2, PYGL, TERT, TYR, XDH |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.651E-05 | 8.854E-04 | HPGD, MMP2, MMP9, TERT |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.690E-05 | 9.021E-04 | ADRA2A, AKT1, CDC25B, ESR1, GSK3B, HIF1A, MAPK1, NEK6, PIK3R1, PKN1, PTK2, PTPN1, SRC, SYK, TP53 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.729E-05 | 9.205E-04 | AXL, CDK1, CSNK2A1, FLT3, PKM, PPARG |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.896E-05 | 9.877E-04 | ADRA2A, AKT1, FFAR1, HIF1A, NOX4, PIK3R1, PPARG, PYGL |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.946E-05 | 1.012E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.086E-05 | 1.067E-03 | IGF1R, KDR, PTK2, SRC, SYK |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 2.493E-05 | 1.243E-03 | AKR1B1, AKT1, AR, CFTR, PPARG, SRC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.808E-05 | 1.383E-03 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.904E-05 | 1.424E-03 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.038E-05 | 1.480E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HCAR2, HPGD, HTT, MAPT, MMP9, NOX4, PPARG, PTGS2, SRC, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.083E-05 | 1.489E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, MPO, NFKB1, PPARD, PTGS2, SRC |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.507E-05 | 1.663E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.810E-05 | 1.780E-03 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.127E-05 | 1.904E-03 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 4.127E-05 | 1.904E-03 | PPARG, SRC, TP53 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 4.127E-05 | 1.904E-03 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 4.289E-05 | 1.970E-03 | ALOX5, CXCR1, FABP5, GAA, GLA, MAPK1, MMP9, MPO, NFKB1, PKM, PYGL, TLR2, TTR |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 4.470E-05 | 2.040E-03 | AKT1, FABP3, PPARA, PPARG |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 4.470E-05 | 2.040E-03 | AKT1, MAPT, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 4.538E-05 | 2.059E-03 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.067E-05 | 2.257E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.067E-05 | 2.257E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 5.067E-05 | 2.257E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.067E-05 | 2.257E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.067E-05 | 2.257E-03 | ALOX12, ALOX15 |
| MF | Unclassified; | GO:0032403; protein complex binding | 5.331E-05 | 2.350E-03 | ACHE, ADRA2A, APEX1, FLT3, IGF1R, KDR, MMP13, MMP9, P4HB, PIK3R1, PKM, PPARA, PTPN1, SRC, SYK, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 5.435E-05 | 2.391E-03 | ADRA2A, AKT1, CFTR, DRD4, FFAR1, HTT, NPSR1, PLA2G1B, SLC6A1 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 5.645E-05 | 2.459E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 5.645E-05 | 2.459E-03 | GSK3B, HTT, MAPT |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.744E-05 | 2.497E-03 | ABCG2, CA12, CA2, CA7, CFTR, DRD4, ESR1, HIF1A, HTT, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPA1 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 6.152E-05 | 2.653E-03 | AKT1, HIF1A, MMP9, PTGS2, PTPN1, SRC |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 6.380E-05 | 2.729E-03 | AKT1, ALK, AR, ESR1, ESR2, NFKB1, PLA2G1B, PPARG, TLR2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 6.756E-05 | 2.862E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 7.488E-05 | 3.118E-03 | ESR1, MAPK1, STAT6 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 8.042E-05 | 3.317E-03 | ADRA2A, ADRA2B, ADRA2C, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, HCAR2, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, PPARG, TSHR |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 8.525E-05 | 3.509E-03 | ABCC1, ADRA2A, ADRA2B, ADRA2C, ALK, AXL, BACE1, CFTR, DRD4, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, IGF1R, KDR, MET, NPC1, NPSR1, SLC6A1, SLC6A11, TLR2, TRPA1, TSHR |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 9.660E-05 | 3.912E-03 | CDK6, GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 9.683E-05 | 3.912E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.013E-04 | 4.071E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.115E-04 | 4.446E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 1.161E-04 | 4.620E-03 | APEX1, AR, AURKB, BLM, CDK1, CSNK2A1, ESR1, PPARD, STAT6, TERT, TNKS, TNKS2, TP53 |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 1.193E-04 | 4.714E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG, SYK |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.226E-04 | 4.827E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.257E-04 | 4.923E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.267E-04 | 4.944E-03 | CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.285E-04 | 4.997E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, HTT, KDR, PPARA, PTK2, PTPN1 |
| BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 1.307E-04 | 5.060E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, KMT2A, NOX4, SRC, TERT |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.513E-04 | 5.700E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.513E-04 | 5.700E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.513E-04 | 5.700E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.513E-04 | 5.700E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.513E-04 | 5.700E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.524E-04 | 5.714E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.525E-04 | 5.714E-03 | MMP2, MMP9, PPARD, PTGS2 |
| MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 1.534E-04 | 5.738E-03 | ESR1, ESR2, KMT2A, PPARG, STAT6, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.568E-04 | 5.845E-03 | AR, CDK6, CYP1B1, FABP3, KMT2A, LMNA, NOX4, PKN1, PPARD, PPARG, PTGS2, TERT, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.649E-04 | 6.077E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.773E-04 | 6.455E-03 | CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.858E-04 | 6.675E-03 | AXL, FLT3, HIF1A, KMT2A, PKN1, POLB |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.858E-04 | 6.675E-03 | AHR, AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0032502; developmental process | GO:0031214; biomineral tissue development | 2.000E-04 | 7.093E-03 | ALOX15, ALPL, MMP13, PPARA, PTGS2 |
| BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 2.235E-04 | 7.838E-03 | ADRA2A, CAMK2B, DRD4, FFAR1, HTT, NPSR1, PLA2G1B, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 2.255E-04 | 7.868E-03 | AKT1, CYP1B1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.255E-04 | 7.868E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.255E-04 | 7.868E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 2.553E-04 | 8.795E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 2.670E-04 | 9.140E-03 | CYP1A2, ESR1, ESRRA, HPGD, PTGS2, SLC6A1 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.691E-04 | 9.186E-03 | AKT1, HIF1A, TERT |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 2.712E-04 | 9.200E-03 | AKT1, HIF1A, KDR, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.712E-04 | 9.200E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0016209; antioxidant activity | GO:0004601; peroxidase activity | 2.712E-04 | 9.200E-03 | GSTK1, MPO, PTGS1, PTGS2 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 2.788E-04 | 9.442E-03 | CFTR, CYP19A1, FFAR1, HCAR2, HIF1A, PPARD |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.961E-04 | 9.918E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 3.012E-04 | 9.952E-03 | NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.012E-04 | 9.952E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006145; purine nucleobase catabolic process | 3.012E-04 | 9.952E-03 | GDA, XDH |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.012E-04 | 9.952E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.012E-04 | 9.952E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 3.012E-04 | 9.952E-03 | SLC6A1, SLC6A11 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 3.012E-04 | 9.952E-03 | ALDH1A1, AR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.197E-21 | 7.973E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.885E-16 | 2.053E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.402E-14 | 2.306E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.196E-14 | 3.367E-11 | AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, GDA, GLO1, KMT2A, MMP1, MMP13, MMP2, MMP3, MMP9, NR1I2, PPARA, PPARD, PPARG, PTPN1, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.344E-20 | 2.700E-18 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.997E-12 | 4.017E-10 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.083E-11 | 7.256E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.054E-10 | 1.630E-08 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.467E-10 | 1.240E-08 | CYP2C9; GSTK1; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.761E-09 | 5.058E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.479E-09 | 1.224E-07 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.143E-08 | 3.528E-07 | GDA; PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD17B1; ALOX5; HSD17B2; XDH; GAA; TYR; CYP2C9; CYP2C8; CYP2A6; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.446E-09 | 1.117E-07 | HPGD; KMT2A; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.784E-10 | 2.943E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.939E-08 | 3.528E-07 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.790E-08 | 3.738E-07 | GABBR1; SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.181E-08 | 2.374E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.055E-07 | 1.178E-06 | GSK3B; SYK; PIK3R1; PTK2; NFKB1; IGF1R; CDK6; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.457E-08 | 4.343E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.026E-08 | 8.307E-07 | CDK6; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.457E-08 | 3.528E-07 | CYP2C9; GSTK1; CYP2C8; CYP2A6; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.457E-08 | 3.528E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.849E-07 | 1.770E-06 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.267E-07 | 1.340E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.043E-07 | 1.867E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTGS2; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.187E-07 | 2.669E-06 | CAMK2B; CDK6; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.243E-06 | 9.254E-06 | HCAR2; CAMK2B; GABBR1; AKT1; MAPK1; PIK3R1; PPARA; CFTR; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.627E-06 | 1.127E-05 | POLB; CDK6; PKM; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.882E-07 | 4.729E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.433E-07 | 1.440E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.187E-07 | 2.669E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.620E-06 | 1.127E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.124E-07 | 5.507E-06 | CYP2C9; GSTK1; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.358E-06 | 1.441E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.181E-06 | 1.441E-05 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.966E-06 | 3.784E-05 | ABCC1; CDK6; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1; CDC25B |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.696E-06 | 2.697E-05 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.366E-06 | 1.441E-05 | ALK; CDK6; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.296E-06 | 3.859E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.141E-05 | 5.333E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.126E-05 | 5.333E-05 | MMP3; AKT1; MAPK1; PIK3R1; PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.060E-05 | 5.333E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.366E-06 | 1.441E-05 | FABP4; AKT1; PIK3R1; PTGS2; TSHR; PTGS1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.258E-06 | 3.494E-05 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.988E-05 | 8.878E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.127E-05 | 5.333E-05 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.738E-05 | 1.964E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.127E-05 | 5.333E-05 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.859E-05 | 1.650E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.150E-05 | 3.033E-04 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 7.165E-05 | 2.717E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.052E-05 | 2.385E-04 | CDK1; AKT1; MAPK1; PIK3R1; CDC25B; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.788E-05 | 1.964E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.220E-05 | 5.571E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.823E-04 | 6.319E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.693E-04 | 5.970E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.031E-04 | 6.802E-04 | SYK; SRC; AKT1; MAPK1; PIK3R1; PTGS1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.392E-04 | 7.883E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1; TLR2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.856E-04 | 6.322E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.260E-04 | 1.317E-03 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.109E-04 | 1.008E-03 | SYK; AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 6.646E-04 | 1.994E-03 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.881E-04 | 2.005E-03 | GABBR1; GABRR1; NMUR2; ADRA2C; ADRA2B; ADRA2A; DRD4; TSHR |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 4.100E-04 | 1.288E-03 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 5.907E-04 | 1.799E-03 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.913E-05 | 1.273E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 6.777E-04 | 2.003E-03 | CAMK2B; PKM; AKT1; PYGL; PPARA |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.862E-05 | 2.653E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.074E-03 | 2.840E-03 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA2A |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 3.600E-04 | 1.149E-03 | GABBR1; GABRR1; SRC; SLC6A11; SLC6A1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 9.271E-05 | 3.388E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 7.740E-04 | 2.190E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.038E-03 | 2.782E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.436E-04 | 2.323E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.740E-04 | 2.190E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.119E-03 | 4.953E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.639E-03 | 4.066E-03 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.063E-03 | 6.996E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.698E-03 | 4.112E-03 | AKT1; PPARG; PIK3R1; CFTR; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 3.063E-03 | 6.996E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.252E-03 | 7.345E-03 | SYK; CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.020E-03 | 4.833E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.698E-03 | 4.112E-03 | GSK3B; CDK6; CDK1; TP53; CDC25B |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.982E-03 | 8.425E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.822E-03 | 9.890E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 4.822E-03 | 9.890E-03 | CAMK2B; SRC; MAPK1; PIK3R1; PTGS2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.606E-03 | 1.632E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.374E-03 | 1.425E-02 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.231E-03 | 1.216E-02 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.251E-03 | 1.722E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 3.648E-03 | 8.057E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.943E-03 | 8.425E-03 | SYK; AKT1; MAPK1; PIK3R1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.942E-02 | 3.307E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 5.103E-03 | 1.026E-02 | CAMK2B; GSK3B; MAPK1; TYR |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.255E-03 | 3.235E-03 | SYK; AKT1; MAPK1; PIK3R1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 9.084E-03 | 1.706E-02 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.286E-03 | 1.042E-02 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.363E-02 | 2.362E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.634E-03 | 4.066E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 5.103E-03 | 1.026E-02 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.943E-03 | 8.425E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.167E-02 | 2.076E-02 | GSK3B; MAPK1; MET; PTK2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.286E-03 | 1.042E-02 | FAAH; GABRR1; MAPK1; PTGS2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.085E-03 | 4.931E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.844E-04 | 2.190E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.474E-03 | 3.751E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.255E-03 | 3.235E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.884E-02 | 4.601E-02 | CA2; PLA2G1B; CFTR |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.443E-02 | 3.959E-02 | MMP1; MMP3; TLR2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.304E-02 | 3.796E-02 | SRC; CDK1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.170E-02 | 3.605E-02 | MAPK1; PKN1; NFKB1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.459E-02 | 2.506E-02 | CAMK2B; CA2; CFTR |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.257E-02 | 2.196E-02 | AKT1; PPARA; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.209E-02 | 2.131E-02 | CDK6; CDK1; TP53 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 9.855E-03 | 1.817E-02 | AKT1; PIK3R1; IGF1R |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.028E-02 | 1.862E-02 | SRC; MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.028E-02 | 1.862E-02 | STAT6; NFKB1; TLR2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.635E-04 | 5.870E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.883E-03 | 1.509E-02 | AKR1B10; AKR1B1; GLA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.173E-05 | 2.080E-04 | AKR1B10; GAA; AKR1B1; GLA |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.431E-03 | 9.278E-03 | PKM; MAPK1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.928E-03 | 8.425E-03 | CYP2A6; CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.462E-03 | 7.731E-03 | ABCC1; CFTR; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.965E-02 | 4.693E-02 | MAPK1; PIK3R1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.030E-03 | 2.782E-03 | MAPK1; PPARG; TP53 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 3.108E-02 | 4.880E-02 | PKM; GLO1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.424E-02 | 3.959E-02 | MAOA; TYR |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.170E-02 | 3.605E-02 | POLB; APEX1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.048E-02 | 3.459E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.555E-02 | 4.109E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.088E-02 | 1.952E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.182E-06 | 1.881E-05 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PTGS2; PTGS2; MMP1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PTGS1; PTGS2; FAAH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; PPARG |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| NA: NA | HIV infections | NA | AHR |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1; HCAR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; TYR; MMP1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PPARG; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; TLR2; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; CDC25B; TP53; ESR1; ESR1; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C; ADRA2B |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; PKM; SYK; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HCAR2; KDR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; PTGS2; NFKB1; PPARG; PPARG; PPARD; HCAR2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; ESR1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; FLT3; MMP2; PTGS2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; ADRA2C; ADRA2A; TRPA1; FAAH; ESR1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; TYR; KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; TERT; FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; ADRA2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARG; PPARD; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; IGF1R; IGF1R; AXL; KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; FFAR1; GSK3B; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; PPARD; HCAR2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; PTGS2; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH; HCAR2 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |